Related Experiment Video
Updated: Jun 15, 2025

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
Targeting toll-like receptors: unveiling potential therapeutic strategies for deep vein thrombosis
Wei Shao1,2, Zilong Wang1,2, Jian Wu1,2
1The First Clinical College, Gannan Medical University, Ganzhou, China.
Abstract:
Deep vein thrombosis (DVT) is a complex multifactorial vascular disease characterized by abnormal blood stasis and coagulation within the deep veins, primarily occurring in the lower limbs. This pathological condition not only causes local circulatory disruption but also has the potential to trigger life-threatening pulmonary embolism through thrombus detachment, thus posing a major threat to human health. Toll - like receptors (TLRs), essential components of the innate immune system, have been increasingly acknowledged as crucial determinants in the pathogenesis of DVT. TLRs possess the ability to recognize a diverse range of pathogen - associated molecular patterns (PAMPs) and endogenous danger - associated molecular patterns (DAMPs). Upon activation, they trigger a cascade of inflammatory responses that are intricately intertwined with the thrombotic process. This review comprehensively scrutinizes the extant knowledge pertaining to the role of TLRs in DVT. It systematically synthesizes the molecular mechanisms underpinning the participation of TLRs in DVT, spanning platelet activation, endothelial cell dysfunction, and leukocyte recruitment. Moreover, it delves profoundly into the potential of targeting TLRs as therapeutic strategies for DVT. This entails the exploration of the development and application of TLR inhibitors or antagonists. By elucidating these aspects, the objective is to proffer novel perspectives and insights for the prevention and treatment of DVT.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

